PROKIDNEY CORP.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
PROK$1.15+0.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share data)
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Cash and cash equivalents | $101,895 | $108,537 |
| Marketable securities | 123,049 | 161,480 |
| Interest receivable | 1,032 | 1,127 |
| Prepaid assets | 3,083 | 2,808 |
| Prepaid clinical | 4,049 | 3,923 |
| Other current assets | 1,794 | 2,804 |
| Total current assets | 234,902 | 280,679 |
| Fixed assets, net | 54,441 | 51,231 |
| Right of use assets, net | 3,441 | 3,664 |
| Total assets | $292,784 | $335,574 |
| Liabilities and Stockholders' Deficit | ||
| Accounts payable | $2,592 | $940 |
| Lease liabilities | 1,108 | 1,071 |
| Accrued expenses and other | 22,231 | 28,731 |
| Income taxes payable | – | – |
| Total current liabilities | 25,931 | 30,742 |
| Income tax payable, net of current portion | 1,074 | 1,074 |
| Lease liabilities, net of current portion | 2,675 | 2,965 |
| Total liabilities | 29,680 | 34,781 |
| Commitments and contingencies | ||
| Redeemable noncontrolling interest | 1,286,887 | 1,311,990 |
| Stockholders’ deficit | ||
| Class A common stock, $0.0001 par value; 700,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 141,980,643 and 141,807,277 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 14 | 14 |
| Class B common stock, $0.0001 par value; 500,000,000 shares authorized; 159,973,334 and 159,262,779 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 16 | 16 |
| Additional paid-in capital | 266,112 | 258,552 |
| Accumulated other comprehensive (loss) gain | (53) | 56 |
| Accumulated deficit | (1,289,872) | (1,269,835) |
| Total stockholders' deficit | (1,023,783) | (1,011,197) |
| Total liabilities and stockholders' deficit | $292,784 | $335,574 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.